INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE
06/01/2024

Tempus Presentation at the 2024 ASCO® Annual Meeting

Transforming Precision Medicine: AI and Molecular Insights Intersect Across the Cancer Care Continuum
Speakers Ezra Cohen, MD, FASCO
Chief Medical Officer of Oncology, Tempus

Kate Sasser, PhD
Chief Scientific Officer, Tempus

Halla Nimeiri, MD
Chief Development Officer, Tempus

Related Content

View more